ReviewDie Ophthalmologie2026
[Pioneering trials in ophthalmology-From clinical trials to guideline treatment].
Review in Die Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The path from a clinical study to guideline-based treatment is often long and shaped by the interaction of numerous stakeholders. Scientific institutions, industrial and academic sponsors, national and international regulatory authorities and medical professional societies all contribute to translating scientific findings into evidence-based treatment recommendations. Clinical trials represent the central instrument for generating clinical evidence and form the foundation for regulatory decisions and for the development of modern treatment strategies. Using selected examples from ophthalmology this article illustrates how diverse the developmental pathways of new therapies can be, from the first clinical evidence to the integration into clinical guidelines. In addition, it highlights how clinical studies continue to support guideline development and enrich everyday clinical practice beyond the initial approval of new drugs. In this way, it becomes clear how clinical studies shape the entire translational process, from scientific innovation and regulatory evaluation to the establishment of treatment in guidelines and routine clinical care.
Indexed as
Identifiers
42417986What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.